Fotio, Yannick http://orcid.org/0000-0001-5193-2009
Mabou Tagne, Alex http://orcid.org/0000-0003-3986-8344
Squire, Erica
Lee, Hye-lim
Phillips, Connor M.
Chang, Kayla http://orcid.org/0009-0000-0986-273X
Ahmed, Faizy
Greenberg, Andrew S. http://orcid.org/0000-0001-5062-387X
Villalta, S. Armando
Scarfone, Vanessa M.
Spadoni, Gilberto
Mor, Marco http://orcid.org/0000-0003-0199-1849
Piomelli, Daniele http://orcid.org/0000-0002-2983-774X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (1R01DA055578-01)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1K99AT012658-01)
U.S. Department of Health & Human Services | NIH | National Center for Complementary and Integrative Health (1K99AT012658-01)
Article History
Received: 14 August 2023
Accepted: 15 February 2024
First Online: 24 February 2024
Competing interests
: D.P. and M.M. are inventors in patents that protect ARN19702 and other NAAA inhibitors, owned by the University of California, the University of Parma, the University of Urbino, and the Fondazione Istituto Italiano di Tecnologia (no. 13/898,225, filed 20 May 2013, published 3 April 2014; no. 62/337,744, filed 17 May 2016, published 23 November 2017). D.P. and Y.F. are inventors in a patent application that protects the algostatic effects of NAAA inhibitors, filed by the University of California (no. 63/166,134, filed 25 March 2021, published 29 September 2022). The other authors declare no competing interest. No specific aspect of the manuscript was covered in patent applications.